Intimation of closure of trading window from 1st October, 2026 to 31st October, 2026 (both days inclusive), for the purpose of approval of unaudited financial results for the quarter and ....

Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Financial ....

Kindly refer the attachment.

We would like to inform that the Company has acquired 9.21% stake in Torrent Urja 19 Private Limited.

Please find enclosed herewith intimation with respect to incorporation of wholly owned subsidiary of the Company in Brazil.

Enclosed please find herewith details of Investor meet.

Please find attached herewith proceedings of the 15th Annual General Meeting of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) held on 8th September, 2026.

Please find attached herewith Scrutinizer''s Report.

Enclosed please find herewith details of Investor meet.

Enclosed please find herewith Investor meet details.

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meetings

Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.

Enclosed please find herewith Press Release with respect to Acquisition.

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

Please find enclosed herewith Newspaper Advertisement of Notice of 15th Annual General Meeting and E-Voting information.

Please find enclosed herewith the Business Responsibility & Sustainability Report for FY 2025-26

Please find enclosed herewith Integrated Annual Report FY 2025-26 under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find attached herewith Notice convening the 15th Annual General Meeting.

Enclosed please find herewith details of investor meet.

Please find attached herewith details of Analyst/Investor meet.

Please find attached herewith transcript of Earnings call held on 31 July, 2026.

Intimation of 15th Annual General Meeting and Record date.

Newspaper Advertisement for 15th Annual General Meeting (AGM)

Intimation of Record date for Dividend.

Enclosed please find herewith unaudited financial results for the first quarter ended June 30, 2026.

Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve the Unaudited Financial ....

Enclosed please find herewith the details of Earnings Call slated for Friday, July 31, 2026 from 8:30 a.m. to 9:30 a.m. (IST), for your information and record.

Intimation of closure of Trading Window from 1st July, 2026 to 1st August, 2026 (both days inclusive), for the purpose of approval of unaudited financial results for the quarter ended 30th June, 2026.

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Institutional Investor Meeting - Plant Visit

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Analyst / Institutional Investor Meeting.

Please find enclosed herewith transcript of Earnings Call held on 15th May, 2026, which is also made available on the website of the Company.

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

We hereby confirm that we have uploaded audio recording of the Q4 & FY2025-26 Earnings Call held on May 15, 2026 on the website of the Company.

We wish to inform you that the Board of Directors at its meeting held today i.e., May 14, 2026, has inter-alia approved the Audited Financial Results for the quarter and year ended March ....

Please find enclosed herewith Investors Presentation for Q4 & FY 2025-26

Enclosed please find herewith Audited financial results for the quarter and year ended March 31, 2026

Enclosed please find herewith intimation with respect to allotment of Equity Shares under the "Employee Stock Option Scheme, 2021".

Enclosed please find herewith Press Release of the Company for the fourth quarter and year ended March 31, 2026.

Enclosed please find herewith the details of Earnings Call slated for Friday, May 15, 2026 from 8:30 a.m. to 9:30 a.m. (IST), for your information and record.

Please find attached herewith Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2026.

Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve the Audited Financial ....

Intimation of closure of trading window from April 1, 2026 to May 16, 2026 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2026.

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Kindly refer attachment.

Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

Kindly refer attachment.

Kindly refer the enclosed attachment.